BioCentury In Depth
The Inflation Reduction Act
The Inflation Reduction Act, signed into law on Aug. 16, 2022, set in motion broad-based drug price regulation as well as changes to the Medicare program that are fundamentally reshaping the drug development ecosystem. A comprehensive knowledge of the law has become essential for drug development decision-making, including for investments and pipeline prioritization.
BioCentury is providing deep analysis of the law, exploring its impacts and explaining how the federal government is implementing it. This analysis is complemented by perspectives from business and policy leaders on options for medical product developers to navigate the new landscape, and reporting on the biopharmaceutical industry’s attempts to modify or derail the IRA through litigation and legislation.
Sign up now and put BioCentury to work for you.
Complimentary access with registration
Analysis of Eliquis, Xarelto spotlights complexities of Inflation Reduction Act
CMS avoided cancer drugs, prioritized volume over cost to Medicare
Available to BioCentury Subscribers Only